NUV-1511 drug-drug conjugate (DDC) to enter the clinical stage: phase 1

[Maxone73]

"Dosing the first patient with NUV-1511 marks a significant milestone for our proprietary DDC platform, from which we are developing potent oncology-focused chimeric small molecules designed to selectively deliver anti-cancer therapeutics to cancer cells, while mitigating effects on healthy non-target tissues,"

The study will initially evaluate safety and tolerability, pharmacokinetic profile, and assess for signs of clinical activity in patients with advanced solid tumors who previously received and progressed on or after treatment with Enhertu® and/or Trodelvy® per approved U.S. Food and Drug Administration (FDA) labeling, human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), advanced pancreatic cancer, and platinum-resistant ovarian cancer (PROC).

finance.yahoo.com/news/nuva...

[Scout4answers]

The ability to stop cancer keeps getting closer.

[Maxone73 in reply to Scout4answers]

In these past weeks I have noticed increased activity about new drug delivery techniques!

[j-o-h-n in reply to Maxone73]

It's my theory that dying is the true way to stop Ca.....

Good Luck, Good Health and Good Humor.

j-o-h-n

[Maxone73 in reply to j-o-h-n]

I cannot say that you are technically wrong

[j-o-h-n in reply to Maxone73]

That's exactly what I say to my wife...(GMTA)...

Good Luck, Good Health and Good Humor.

j-o-h-n